Skip to content
Menu

Nuvectis Pharma, Inc. NVCT

Full chart Compare
Set alert

Price alert · NVCT

All alert types
19.84 USD -0.45 (-2.22%)

Regular-session close

20.40 +0.56 +2.82%

After hours · Nov 19, 4:00 PM ET

19.74 Day range 20.48
5.77 52-week range 29.28
YTD
+162.78%
1 year
+232.33%

5D -1.93 (-9.13%)

19202122WedThuFriMonTue19.20
Market cap
682.28M
EPS (ttm)
-2.00
Shares out
19.32M
Forward P/E
-4.77
YTD return
+162.78%
1-year return
+232.33%
50-day average
6.43
200-day average
6.80
Volume
156.98K
Avg volume
205.84K
Open
20.48
Previous close
20.29
Day's range
19.74 – 20.48
52-week range
5.77 – 29.28
Beta
0.40
Price target
22.00 (+10.9%)

Key statistics

Enterprise value
70.16M
Price / book
7.91
Free cash flow
-6.31M
Total cash
17.17M
Return on equity
-140.00%
Short % of float
13.99%

Fundamental scorecard

6 of 25 checks passed on NVCT’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
NVCT Revenue — quarterly 0
NVCT Net income — quarterly -30.07M
NVCT EPS — quarterly -1.02

Earnings

NVCT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2024Sep 1, 2024-0.26-0.24+0.02+7.69%
Aug 6, 2024Jun 1, 2024-0.26———
Aug 6, 2024Jun 1, 2024-0.26-0.260.000.00%
May 7, 2024Mar 1, 2024-0.40-0.25+0.15+37.50%
May 7, 2024Mar 1, 2024-0.40———
Mar 5, 2024Dec 1, 2023-0.40———

Upgrades / downgrades

NVCT analyst upgrades and downgrades
DateFirmActionFromTo
Aug 6, 2024HC Wainwright & Co.reitBuyBuy
May 8, 2024HC Wainwright & Co.reitBuyBuy
Sep 15, 2023HC Wainwright & Co.reitBuyBuy
Mar 7, 2023HC Wainwright & Co.reit—Buy
Feb 10, 2023HC Wainwright & Co.reit—Buy
Jul 13, 2022Ladenburg Thalmanninit—Buy

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
nuvectis.com

News

Your note

Sign in to keep a note on NVCT — it syncs with the Stock Master app.

Insider holders

NVCT insider holders
InsiderRelationLatest transactionDateShares held
BENTSUR RONChief Executive OfficerPurchaseNov 14, 20243,266,420
CARSON MICHAEL J.OfficerSaleNov 6, 202487,918
HOBERMAN KENNETHDirectorStock Award(Grant)Jun 12, 2024103,140
KAPLAN MATTHEW L.DirectorStock Award(Grant)Jun 12, 202483,760
MOSSERI MARLIO CHARLESBeneficial Owner of more than 10% of a Class of SecurityPurchaseDec 12, 20242,612,000
OLIVIERO JAMES F IIIDirectorStock Award(Grant)Jun 12, 202457,828

Institution ownership

NVCT institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc1.56%301,1381.38MSep 29, 2024
Baldwin Wealth Partners LLC/MA0.90%174,130797.51KSep 29, 2024
Geode Capital Management, LLC0.41%79,716365.10KSep 29, 2024
Millennium Management Llc0.35%68,499313.73KSep 29, 2024
Iridian Asset Management LLC0.29%55,380253.64KSep 29, 2024
Gsa Capital Partners Llp0.26%50,129229.59KSep 29, 2024

Fund ownership

NVCT fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.20%231,0401.06MSep 29, 2024
Vanguard Extended Market Index Fund0.30%57,030261.20KSep 29, 2024
Fidelity Extended Market Index Fund0.19%37,447171.51KOct 30, 2024
iShares Micro Cap ETF0.11%21,21897.18KOct 30, 2024
Fidelity Total Market Index Fund0.07%13,31060.96KOct 30, 2024
Fidelity Series Total Market Index Fund0.05%8,93840.94KOct 30, 2024